Clinical Trial Results:
Intravenous low-dose decitabine versus supportive care in elderly patients with
primary Myelodysplastic Syndrome (MDS) (>10 % blasts or high-risk cytogenetics),
secondary MDS or Chronic Myelomonocytic Leukemia (CMML) who are not
eligible for intensive therapy: an EORTC-German MDS Study Group randomized
phase III study
Summary
|
|
EudraCT number |
2005-002830-36 |
Trial protocol |
CZ |
Global completion date |
04 Jun 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
15 Dec 2016
|
First version publication date |
15 Dec 2016
|
Other versions |
|
Summary report(s) |
Short study report to Authorities |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.